Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$29.65
-$0.39(-1.54%)
At close: 4:00 PM EST
$29.65
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$10.60 - $30.48
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.18M
Market Cap
$3.06B
Enterprise Value$3.10B
Total Cash (Recent Filing)$563.34M
Total Debt (Recent Filing)$4.18M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Feb 19, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding105,868,430
10 Day Avg. Volume1,130,489
30 Day Avg. Volume1,178,388
Financial Highlights & Ratios
PEG Ratio2.41
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-22.36
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.95
Forecast
1Y Price Target
$36.83Price Target Upside24.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySustained clinical activity observed in EDG-7500 25 mg cohorts across key hypertrophic cardiomyopathy markers supports potential benefit in both obstructive and non-obstructive patient groups and informs Phase 3 planning.
Pipeline Diversification And FundingExpansion of the clinical pipeline with programs like EDG-15400 and sevasemten, combined with a robust balance sheet, lowers funding risk and supports advancement toward pivotal readouts.
Trial Enrollment And Data ReadoutStrong enrollment in CIRRUS-HCM Part D and an upcoming full 12-week readout should clarify exposure-response relationships and guide biomarker-driven dose optimization for later-stage trials.
Bears Say
Dosing And Competitive DifferentiationReliance on titration for EDG-7500, once a differentiator, may erode competitive advantage if atrial fibrillation concerns force more conservative dosing or restrictive labeling compared with other cardiac myosin inhibitors.
Investor Sentiment And Timeline RiskSharp share declines tied to AFib concerns have increased investor skepticism and may temper expectations or delay favourable positioning ahead of the Phase 3 Becker muscular dystrophy readout expected in late 2026.
Safety UncertaintyAdditional new-onset atrial fibrillation cases in Part D introduce ongoing safety uncertainty that could complicate regulatory assessment and narrow the eligible patient population for EDG-7500.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $10.60 and its highest was $30.48 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $3.06B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 14 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 105,868,430 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -1.612%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.83 (24.22% Upside)
$36.83 (24.22% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▼ 12.3%
Last 30 Days ▼ 12.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.14%
12-Months-Change
Fundamentals
Return on Equity
-30.02%
Trailing 12-Months
Asset Growth
14.12%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$36.83
▲(24.22% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.38% Insiders
11.34% Mutual Funds
75.37% Other Institutional Investors
3.33% Public Companies and
Individual Investors